Halwe, Nico Joel https://orcid.org/0000-0002-7983-2808
Cool, Konner https://orcid.org/0000-0003-3666-0214
Breithaupt, Angele https://orcid.org/0000-0002-6373-5923
Schön, Jacob https://orcid.org/0000-0002-9801-7972
Trujillo, Jessie D.
Nooruzzaman, Mohammed https://orcid.org/0000-0002-9358-1494
Kwon, Taeyong
Ahrens, Ann Kathrin https://orcid.org/0009-0007-3635-423X
Britzke, Tobias https://orcid.org/0009-0001-8177-4766
McDowell, Chester D. https://orcid.org/0000-0001-8452-7288
Piesche, Ronja
Singh, Gagandeep https://orcid.org/0000-0003-3260-2631
Pinho dos Reis, Vinicius
Kafle, Sujan https://orcid.org/0009-0001-0423-6745
Pohlmann, Anne https://orcid.org/0000-0002-5318-665X
Gaudreault, Natasha N.
Corleis, Björn
Ferreyra, Franco Matias
Carossino, Mariano https://orcid.org/0000-0003-3864-5915
Balasuriya, Udeni B. R.
Hensley, Lisa
Morozov, Igor
Covaleda, Lina M.
Diel, Diego G. https://orcid.org/0000-0003-3237-8940
Ulrich, Lorenz https://orcid.org/0000-0001-5004-806X
Hoffmann, Donata https://orcid.org/0000-0003-4552-031X
Beer, Martin https://orcid.org/0000-0002-0598-5254
Richt, Juergen A. https://orcid.org/0000-0001-7308-5672
Article History
Received: 9 August 2024
Accepted: 17 September 2024
First Online: 25 September 2024
Competing interests
: The J.A.R. laboratory received support from Tonix Pharmaceuticals, Genus plc, Xing Technologies and Zoetis outside of the reported work. J.A.R. is inventor on patents and patent applications, owned by Kansas State University, on the use of antivirals and vaccines for the treatment and prevention of virus infections. The other authors declare no competing interests.